Biocon Limited and its European partner Zentiva have received regulatory approval for their generic version of Liraglutide in the European Union through the Decentralized Procedure (DCP), the Indian biopharmaceutical company announced on December 24, 2024.

The shares of Biocon Limited were trading at ₹337.25 up by ₹7.70 or 2.34 per cent on the NSE today at 10.34 am.

The approval covers generic versions of two Novo Nordisk products: Victoza, used in the treatment of Type-2 Diabetes, and Saxenda, which is indicated for weight management. This marks a significant milestone in bringing complex formulation alternatives to the European market.

The development represents Biocon’s continued expansion in the European pharmaceutical market and adds to its portfolio of complex generic medications. Liraglutide is part of a class of drugs that has gained considerable attention in recent years for its effectiveness in both diabetes management and weight loss treatment.

• Also read: Stock Market Live Updates 24 December 2024: Sensex, Nifty open flat ahead of Christmas holiday